In an important moment for tuberculosis (TB) control, a new study finds that a shorter regimen to prevent TB can be safely co-administered with dolutegravir (DTG)—the first-line drug to treat HIV in many high-burden TB countries. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI), the study found that weekly administration of rifapentine and…